...
首页> 外文期刊>Neoplasma: Journal of Experimental and Clinical Oncology >Prognostic factors and treatment outcome in 1,516 adult patients with de novo and secondary acute myeloid leukemia in 1999-2009 in 5 hematology intensive care centers in the Czech Republic.
【24h】

Prognostic factors and treatment outcome in 1,516 adult patients with de novo and secondary acute myeloid leukemia in 1999-2009 in 5 hematology intensive care centers in the Czech Republic.

机译:1999-2009年在捷克共和国5个血液病重症监护中心,对1516例成年和继发性急性髓性白血病成人患者的预后因素和治疗结果。

获取原文
获取原文并翻译 | 示例
           

摘要

Acute myeloid leukemia (AML) is a severe condition with a high mortality. When making decisions about the optimal tailor-made therapy, numerous prognostic factors are considered. The study represents a detailed analysis of the role of these factors and treatment outcomes based on a long-term follow-up of patients treated in 5 hematology intensive care centers in the Czech Republic.The studied group comprised 1,188 patients with de novo AML and 328 patients with secondary AML. The latter were significantly older, had more unfavorable cytogenetic changes and less frequently received curative therapy. Curatively treated patients achieved fewer complete remissions and relapsed more often than those with de novo AML. Patients with secondary AML had lower rates of allogeneic transplantation as part of consolidation therapy and a significantly shorter median overall survival. A lower proportion of the patients were alive at the time of analysis. However, the treatment outcome of de novo AML patients is not satisfactory, the only exception being those with acute promyelocytic leukemia. The analysis, which did not evaluate the intention-to-treat criteria and was without randomization, found allogeneic stem cell transplantation to be the most effective modality of consolidation therapy in both groups of patients. .
机译:急性髓细胞性白血病(AML)是一种严重的疾病,死亡率很高。在做出最佳量身定制的治疗方案的决策时,要考虑许多预后因素。这项研究基于对捷克共和国5个血液重症监护中心接受治疗的患者进行的长期随访,详细分析了这些因素的作用和治疗效果,研究组包括1,188例新发AML患者和328例继发性AML患者。后者年龄大得多,细胞遗传学改变更不利,接受治疗的频率更低。经过治疗的患者比从头AML的患者完全缓解率更低,复发率更高。继发性AML患者作为巩固治疗的一部分,异体移植率较低,中位总生存期明显缩短。在分析时,存活的患者比例较低。但是,从头AML患者的治疗结果并不令人满意,唯一的例外是患有急性早幼粒细胞白血病的患者。这项分析没有评估意向性治疗标准,并且没有随机分组,发现同种异体干细胞移植是两组患者中最有效的巩固疗法。 。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号